Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,337 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07344311RecruitingPhase 1
CAR-T cell therapy for advanced prostate cancer
This trial tests a new immunotherapy called A-CAR032, which uses your own immune cells to attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07619534Recruiting
Collecting Spinal Fluid from Advanced Breast Cancer Patients
This study collects spinal fluid samples from people with advanced (metastatic) HER2-positive or triple-negative breast cancer who have never had, and currently do not have, cancer spread to the brain. Researchers want to understand how cancer cells might reach the nervous system and develop better treatments.
Bethesda, MarylandAges 18–120 - NCT01438658Recruiting
Test blood markers to help diagnose metastatic uveal melanoma
This study checks whether blood “biomarkers” (measurable signs in serum) can help diagnose metastatic uveal melanoma. If you have uveal melanoma, the study may look at how useful these blood tests are for spotting spread to other parts of the body.
JerusalemAges Any age - NCT04086290RecruitingPhase 1/Phase 2
Surgery plus targeted radiation for prostate cancer spread
This study looks at whether combining prostate surgery with a highly focused radiation treatment (SBRT) can control prostate cancer that has spread to a limited number of bones. It may help patients by treating the main tumor and the specific metastatic spots in a controlled way.
HerlevAges 18 years+ - NCT03646955Recruiting
Partial breast radiation versus no radiation after lumpectomy
This trial compares giving radiation only to part of the breast versus not giving radiation at all after breast-conserving surgery. It’s meant for women with early, hormone-driven breast cancer to see if skipping radiation can be safe and reduce treatment burden.
SantiagoAges 60 years+ - NCT03591276RecruitingPhase 1/Phase 2
Doxorubicin plus pembrolizumab for hormone-resistant breast cancer
This Phase 1b/2 trial tests a combination of pegylated liposomal doxorubicin and pembrolizumab for breast cancer that no longer responds to hormone treatment. It aims to see how well the combination works and how safely it can be given to patients with advanced disease.
JerusalemAges 18 years+ - NCT03692429RecruitingPhase 1
Testing new immune cells plus chemo for advanced colon cancer
This Phase 1 study tests CYAD-101, an immune-cell treatment made from donor T-cells, given with standard chemotherapy. It is for people with colon or rectal cancer that has spread and has not responded to prior treatments.
Tampa, FloridaAges 18 years+ - NCT04646759RecruitingPhase 3
Fulvestrant or capecitabine plus pyrotinib for metastatic breast cancer
This Phase 3 trial tests adding pyrotinib to standard hormone-based treatments (fulvestrant or capecitabine) to slow or control metastatic breast cancer. It’s for tumors that are hormone-receptor positive and HER2 positive, where standard options have been used before.
Guangzhou, GuangdongAges 18–80 - NCT04019678Recruiting
Breast cancer study after chemotherapy with small underarm node spread
This study looks at whether it’s safe and effective to avoid removing many underarm lymph nodes in some people who, after chemotherapy, still seem to have only tiny (“micro”) cancer deposits in the sentinel lymph node. It may help reduce treatment side effects while keeping cancer control.
Rozzano, MIAges 18–75 - NCT03784651Recruiting
How breast cancer treatment changes metabolism and bone
This study looks at how standard breast cancer treatments affect your body’s metabolism and bones in postmenopausal people with early-stage breast cancer. It may help doctors better predict and prevent bone and metabolic side effects from treatment.
Copenhagen, DanmarkAges 50–70 - NCT04712305Recruiting
Urine test to predict kidney cancer response to immunotherapy
This study uses an at-home-style urine test (urine “omics,” meaning detailed lab information) to help predict how well immunotherapy may work for advanced kidney cancer. If you join, your urine results may help doctors tailor treatment choices and better understand who benefits most.
TaipeiAges 20 years+ - NCT05240950RecruitingPhase 1
CAR-T cell therapy for colorectal cancer in the liver
This Phase 1 study tests an anti-CEA CAR-T cell treatment for people whose colorectal cancer spread to the liver but has been surgically removed with no visible remaining tumor. It aims to see if the treatment can better prevent the cancer from coming back, especially when early warning tests suggest leftover cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04159818RecruitingPhase 2
Adding immune treatments to improve checkpoint drug response in TNBC
This Phase 2 trial tests strategies meant to “prime” the immune system so that immune checkpoint medicines may work better in people with triple-negative breast cancer that has spread (or can’t be fully cured). You might be considered if your cancer has measurable areas that can be biopsied and you meet specific health and prior-treatment rules.
AmsterdamAges 18 years+ - NCT04938986Recruiting
Testing a tumor marker to predict colon cancer relapse risk
This study looks at whether a lab test on your tumor can better predict the chance that non-metastatic colon cancer will come back after surgery. Researchers will compare relapse risk using the Immunoscore® test to help guide follow-up and treatment decisions.
MarseilleAges 18–80 - NCT05339568Recruiting
Smartphone support program for people with advanced lung cancer
This trial tests a “whole process follow-up” care plan, using a smartphone, to support people with non-small cell lung cancer from diagnosis through treatment and follow-up. It may help you manage care steps more smoothly if you’re not a candidate for curative (radical) treatment or don’t want surgery.
Jinan, ShandongAges 18 years+ - NCT04673955Recruiting
Real-world treatment study for metastatic bowel cancer with BRAF mutation
This real-world study looks at how doctors’ standard treatment works for metastatic colorectal cancer that has a specific BRAF mutation (BRAF V600E). It focuses on patients who are already starting—or will soon start—encorafenib plus cetuximab, using routine care rather than extra trial treatment.
Braunau am Inn, Upper AustriaAges 18 years+ - NCT05652192RecruitingPhase 2
SBRT radiation plus chemotherapy and immunotherapy for metastatic nasopharyngeal cancer
This trial tests whether adding targeted radiation (SBRT) to chemotherapy and an immunotherapy drug can help people with metastatic nasopharyngeal cancer live longer and control tumors. It may help by combining local tumor treatment with whole-body immune support.
Hangzhou, ZhejiangAges 18–75 - NCT05537922Recruiting
Study uses data to tailor lung cancer care with immunotherapy
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
Chicago, IllinoisAges 18 years+ - NCT05768503RecruitingPhase 3
Test new drugs after colorectal cancer chemotherapy
This Phase 3 trial compares a new treatment combination (chidamide plus sintilimab plus bevacizumab) versus the standard second-line chemotherapy (FOLFIRI plus bevacizumab) for advanced colorectal cancer that is microsatellite stable/low. It aims to see which treatment works better and is safer for people whose cancer grew after first-line oxaliplatin-based therapy.
Hefei, AnhuiAges 18–75 - NCT05732051RecruitingPhase 2
Nicotinamide riboside to protect the heart during breast cancer chemo
This trial tests whether nicotinamide riboside can help prevent heart problems caused by a common breast-cancer chemotherapy (anthracyclines). If you’re eligible, you’ll be followed to see how your heart is doing during treatment.
Lørenskog, AkershusAges 18 years+ - NCT05054296RecruitingPhase 2
Exercise and Fitbit monitoring to lower heart risk in prostate cancer
This Phase 2 study tests whether a structured exercise and lifestyle program, tracked with a Fitbit, can reduce cardiovascular (heart) risk in men with prostate cancer on hormone therapy. It also checks whether this is safe and feasible while monitoring symptoms and fitness changes.
Houston, TexasAges 18 years+ - NCT05800223RecruitingPhase 3
Armatinib with or without brain radiation for EGFR lung cancer
This study tests whether armatinib alone or combined with focused brain radiation (SRT) can control brain metastases from EGFR-mutated non-small cell lung cancer. It aims to improve outcomes for people with few, mostly low-symptom brain spots.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05699811RecruitingPhase 1/Phase 2
Test of special immune-support cells for solid tumors
This study tests lab-made mesenchymal stromal cells that release interferon alpha (IFNα) for people with locally advanced or metastatic solid cancers. It’s designed to see if this treatment can help when standard treatments have failed or don’t have guideline options.
BeijingAges 18–75 - NCT05817903RecruitingPhase 2
Nivolumab with or without axitinib after prior nivolumab
This Phase 2 trial studies whether adding axitinib to nivolumab (or giving nivolumab alone) can better control advanced clear-cell kidney cancer after standard initial treatment with nivolumab plus ipilimumab. It may help by extending response or slowing tumor growth while improving how long treatment works.
BresciaAges 18 years+
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,337 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.